Heyholder

This is an amended filing · View original →

‹ Back to the disclosure you were reading

GeneOne Life Science, Inc. Q1 revenue KRW 2.6 billion, operating loss of KRW 2.3 billion

GeneOne Life Science, Inc.· Periodic ReportAmended

AI summary · Not investment advice

In Q1, the company sold KRW 2.6 billion worth and lost KRW 2.3 billion from its main business, versus sales of KRW 8.5 billion and a loss of KRW 9.1 billion a year earlier.

Operating profit · 3 months

KRW -2.3 billion

Key facts

Revenue (3 months)
KRW 2.6 billion
Net income (3 months)
KRW -2.4 billion
Period
Q1 (2026.01.01 ~ 2026.03.31)
Revenue (prior-year 3 months)
KRW 8.5 billion
Operating profit (prior-year 3 months)
KRW -9.1 billion
Net income (prior-year 3 months)
KRW -8.8 billion

Commentary

AI commentary · Not investment advice

What happened

GeneOne Life Science reported its consolidated results for the first quarter of 2026, covering January to March. Sales for the three months were KRW 2.58 billion. That is -69.6% from KRW 8.50 billion in the same period a year earlier.

In the company's terms

Operating profit (money earned from the core business) was KRW -2.34 billion for the three months. A year earlier it was KRW -9.07 billion. Net income (the final amount left after all costs and taxes) was KRW -2.38 billion. A year earlier it was KRW -8.84 billion.

Earlier Periodic Report filings from this company

Filings of the same type
FiledTitleKey figure · Note
26.11.16Periodic ReportKRW -5.4 billion

Comments

No comments yet

Comments from shareholders will appear here.